HRP20191961T1 - Spoj imidazodiazepina - Google Patents
Spoj imidazodiazepina Download PDFInfo
- Publication number
- HRP20191961T1 HRP20191961T1 HRP20191961TT HRP20191961T HRP20191961T1 HR P20191961 T1 HRP20191961 T1 HR P20191961T1 HR P20191961T T HRP20191961T T HR P20191961TT HR P20191961 T HRP20191961 T HR P20191961T HR P20191961 T1 HRP20191961 T1 HR P20191961T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- benzoxazol
- dihydro
- salt
- imidazo
- Prior art date
Links
- -1 Imidazodiazepine compound Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 208000028698 Cognitive impairment Diseases 0.000 claims 4
- 208000010877 cognitive disease Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 201000000980 schizophrenia Diseases 0.000 claims 4
- YVAWAKFMHFDJKN-UHFFFAOYSA-N 3-[2-[2-(4-chlorophenyl)-5,6,7,9-tetrahydroimidazo[1,2-a][1,4]diazepin-8-yl]-2-oxoethyl]-4-fluoro-1,3-benzoxazol-2-one Chemical compound ClC1=CC=C(C=C1)C=1N=C2N(CCCN(C2)C(CN2C(OC3=C2C(=CC=C3)F)=O)=O)C=1 YVAWAKFMHFDJKN-UHFFFAOYSA-N 0.000 claims 3
- PKTQTZLCMHCCAN-UHFFFAOYSA-N 4-fluoro-3-[2-oxo-2-[2-[4-(trifluoromethyl)phenyl]-5,6,7,9-tetrahydroimidazo[1,2-a][1,4]diazepin-8-yl]ethyl]-1,3-benzoxazol-2-one Chemical compound FC1=CC=CC2=C1N(C(O2)=O)CC(N1CC=2N(CCC1)C=C(N=2)C1=CC=C(C=C1)C(F)(F)F)=O PKTQTZLCMHCCAN-UHFFFAOYSA-N 0.000 claims 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 3
- GGPWNPHVFLMJPV-UHFFFAOYSA-N 4,5-difluoro-3-[2-oxo-2-(2-phenyl-5,6,7,9-tetrahydroimidazo[1,2-a][1,4]diazepin-8-yl)ethyl]-1,3-benzoxazol-2-one Chemical compound FC1=C(C=CC2=C1N(C(O2)=O)CC(N1CC=2N(CCC1)C=C(N=2)C1=CC=CC=C1)=O)F GGPWNPHVFLMJPV-UHFFFAOYSA-N 0.000 claims 2
- CDDRKYWSMOMULQ-UHFFFAOYSA-N 4-fluoro-3-[2-[2-(2-fluorophenyl)-5,6,7,9-tetrahydroimidazo[1,2-a][1,4]diazepin-8-yl]-2-oxoethyl]-1,3-benzoxazol-2-one Chemical compound FC1=CC=CC2=C1N(C(O2)=O)CC(=O)N1CC=2N(CCC1)C=C(N=2)C1=C(C=CC=C1)F CDDRKYWSMOMULQ-UHFFFAOYSA-N 0.000 claims 2
- XVNQEDYGPSMSPT-UHFFFAOYSA-N 4-fluoro-3-[2-[2-(3-fluorophenyl)-5,6,7,9-tetrahydroimidazo[1,2-a][1,4]diazepin-8-yl]-2-oxoethyl]-1,3-benzoxazol-2-one Chemical compound FC1=CC=CC2=C1N(C(O2)=O)CC(=O)N1CC=2N(CCC1)C=C(N=2)C1=CC(=CC=C1)F XVNQEDYGPSMSPT-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 206010013663 drug dependence Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- GZVUTUDMPJLAFE-UHFFFAOYSA-N 4,5-difluoro-3-[2-oxo-2-(1,3,4,5-tetrahydro-[1,4]diazepino[1,2-a]benzimidazol-2-yl)ethyl]-1,3-benzoxazol-2-one Chemical compound C1N(CCCN2C1=NC1=C2C=CC=C1)C(CN1C(OC2=C1C(=C(C=C2)F)F)=O)=O GZVUTUDMPJLAFE-UHFFFAOYSA-N 0.000 claims 1
- YDTYBKSXZBJQKE-UHFFFAOYSA-N 4-fluoro-3-[2-(8-fluoro-1,3,4,5-tetrahydro-[1,4]diazepino[1,2-a]benzimidazol-2-yl)-2-oxoethyl]-1,3-benzoxazol-2-one Chemical compound FC1=CC=CC2=C1N(C(O2)=O)CC(=O)N1CC2=NC3=C(N2CCC1)C=C(C=C3)F YDTYBKSXZBJQKE-UHFFFAOYSA-N 0.000 claims 1
- 102000004076 Dopamine D1 Receptors Human genes 0.000 claims 1
- 108090000511 Dopamine D1 Receptors Proteins 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940126027 positive allosteric modulator Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (17)
1. Spoj sa formulom (I) ili njegova sol:
u formuli,
R1, R2, i R3 su isti ili različiti jedan od drugog, i oni su H, halogen, niži alkil, ili halo-niži alkil;
R4 je H, halogen, niži alkil, ili halo-niži alkil;
R5 je H;
R6 je fenil koji može biti supstituiran; ili
R5 i R6 mogu formirati benzenov prsten koji može biti supstituiran, zajedno sa atomima ugljika za koje su oni vezani; i
---- je jednostruka veza ili dvostruka veza; i
termin "niži" odnosi se na 1 do 6 ugljikovih atoma.
2. Spoj ili njegova sol u skladu sa patentnim zahtjevom 1, gdje R5 je H, i R6 je fenil koji može biti supstituiran.
3. Spoj ili njegova sol u skladu sa patentnim zahtjevom 2, gdje ---- je jednostruka veza.
4. Spoj ili njegova sol u skladu sa patentnim zahtjevom 3, gdje R4 je H.
5. Spoj ili njegova sol u skladu sa patentnim zahtjevom 4, gdje R1 je H, R2 je H ili halogen, i R3 je halogen.
6. Spoj ili njegova sol u skladu sa patentnim zahtjevom 5, gdje R6 je fenil koji može biti supstituiran sa jednim do četiri RA1koji su isti ili različiti jedan od drugog, i
RA1 je grupa odabrana iz grupe koja se sastoji od -OH, -O-niži alkil, -CN, halogen, niži alkil, halo-niži alkil, niži alkilen-O-niži alkil, -C(=O)-niži alkil, i -C(=O)-niži alkilen-CN.
7. Spoj ili njegova sol u skladu sa patentnim zahtjevom 6, gdje R6 je fenil koji može biti supstituiran sa jednim RA2, i
RA2 je grupa odabrana iz grupe koja se sastoji od halogen, niži alkil, i halo-niži alkil.
8. Spoj ili njegova sol u skladu sa patentnim zahtjevom 7, gdje R2 je H.
9. Spoj ili njegova sol u skladu sa patentnim zahtjevom 8, gdje R6 je fenil koji može biti supstituiran sa jednim RA2 na para-položaju od njegove veze.
10. Spoj ili njegova sol u skladu sa patentnim zahtjevom 1, gdje spoj je odabran iz grupe koja se sastoji od:
4-fluoro-3-(2-okso-2-{2-[4-(trifluorometil)fenil]-6,7-dihidro-5H-imidazo[1,2-a][1,4]diazepin-8(9H)-il}etil)-1,3-benzoksazol-2(3H)-on,
4-fluoro-3-{2-[2-(2-fluorofenil)-6,7-dihidro-5H-imidazo[1,2-a][1,4]diazepin-8(9H)-il]-2-oksoetil}-1,3-benzoksazol-2(3H)-on,
3-[2-(4,5-dihidro-1H-[1,4]diazepino[1,2-a]benzimidazol-2(3H)-il)-2-oksoetil]-4,5-difluoro-1,3-benzoksazol-2(3H)-on,
4-fluoro-3-[2-(8-fluoro-4,5-dihidro-1H-[1,4]diazepino[1,2-a]benzimidazol-2(3H)-il)-2-oksoetil]-1,3-benzoksazol-2(3H)-on,
4,5-difluoro-3-[2-okso-2-(2-fenil-6,7-dihidro-5H-imidazo[1,2-a][1,4]diazepin-8(9H)-il)etil]-1,3-benzoksazol-2(3H)-on,
4-fluoro-3-{2-[2-(3-fluorofenil)-6,7-dihidro-5H-imidazo[1,2-a][1,4]diazepin-8(9H)-il]-2-oksoetil}-1,3-benzoksazol-2(3H)-on, i
3- {2-[2-(4-klorofenil)-6,7-dihidro-5H-imidazo[1,2-a][1,4]diazepin-8(9H)-il]-2-oksoetil}-4-fluoro-1,3-benzoksazol-2(3H)-on.
11. Spoj ili njegova sol u skladu sa patentnim zahtjevom 10, gdje spoj je odabran iz grupe koja se sastoji od:
4-fluoro-3-(2-okso-2-{2-[4-(trifluorometil)fenil]-6,7-dihidro-5H-imidazo[1,2-a][1,4]diazepin-8(9H)-il}etil)-1,3-benzoksazol-2(3H)-on,
4-fluoro-3-{2-[2-(2-fluorofenil)-6,7-dihidro-5H-imidazo[1,2-a][1,4]diazepin-8(9H)-il]-2-oksoetil}-1,3-benzoksazol-2(3H)-on,
4,5-difluoro-3-[2-okso-2-(2-fenil-6,7-dihidro-5H-imidazo[1,2-a][1,4]diazepin-8(9H)-il)etil]-1,3-benzoksazol-2(3H)-on,
4-fluoro-3-{2-[2-(3-fluorofenil)-6,7-dihidro-5H-imidazo[1,2-a][1,4]diazepin-8(9H)-il]-2-oksoetil}-1,3-benzoksazol-2(3H)-on, i
3-{2-[2-(4-klorofenil)-6,7-dihidro-5H-imidazo[1,2-a][1,4]diazepin-8(9H)-il]-2-oksoetil}-4-fluoro-1,3-benzoksazol-2(3H)-on.
12. Spoj ili njegova sol u skladu sa patentnim zahtjevom 10, gdje spoj je 4-fluoro-3-(2-okso-2-{2-[4-(trifluorometil)fenil]-6,7-dihidro-5H-imidazo[1,2-a][1,4]diazepin-8(9H)-il}etil)-1,3-benzoksazol-2(3H)-on.
13. Spoj ili njegova sol u skladu sa patentnim zahtjevom 10, gdje spoj je 3-{2-[2-(4-klorofenil)-6,7-dihidro-5H-imidazo[1,2-a][1,4]diazepin-8(9H)-il]-2-oksoetil}-4-fluoro-1,3-benzoksazol-2(3H)-on.
14. Farmaceutska kompozicija koja sadrži spoj ili njegovu sol u skladu sa patentnim zahtjevom 1 i farmaceutski prihvatljiv ekscipijens.
15. Farmaceutska kompozicija u skladu sa patentnim zahtjevom 14, koja je pozitivni alosterni modulator dopaminskog D1 receptora.
16. Farmaceutska kompozicija u skladu sa patentnim zahtjevom 14, koja je farmaceutska kompozicija za primjenu u prevenciji i/ili liječenju kognitivnog oštećenja, negativnog simptoma šizofrenije, kognitivnog oštećenja povezanog sa šizofrenijom (CIAS), Parkinsonove bolesti, Alzheimerove bolesti, Huntingtonove bolesti, depresije, hiperaktivnog poremećaja sa nedostatkom pažnje (ADHD), ili ovisnosti o lijekovima.
17. Spoj ili njegova sol u skladu sa patentnim zahtjevom 1 za primjenu u metodi za prevenciju i/ili liječenje kognitivnog oštećenja, negativnog simptoma shizofrenije, kognitivnog oštećenja povezanog sa šizofrenijom (CIAS), Parkinsonove bolesti, Alzheimerove bolesti, Huntingtonove bolesti, depresije, hiperaktivnog poremećaja sa nedostatkom pažnje (ADHD), ili ovisnosti o lijekovima.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015123478 | 2015-06-19 | ||
| PCT/JP2016/068080 WO2016204268A1 (ja) | 2015-06-19 | 2016-06-17 | イミダゾジアゼピン化合物 |
| EP16811742.2A EP3312181B1 (en) | 2015-06-19 | 2016-06-17 | Imidazodiazepine compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191961T1 true HRP20191961T1 (hr) | 2020-02-07 |
Family
ID=57546103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191961TT HRP20191961T1 (hr) | 2015-06-19 | 2019-10-30 | Spoj imidazodiazepina |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10426784B2 (hr) |
| EP (1) | EP3312181B1 (hr) |
| JP (1) | JP6658753B2 (hr) |
| KR (1) | KR102591169B1 (hr) |
| CN (2) | CN107635996B (hr) |
| AR (1) | AR105025A1 (hr) |
| AU (1) | AU2016279518B2 (hr) |
| CA (1) | CA2989982C (hr) |
| CO (1) | CO2018000431A2 (hr) |
| CY (1) | CY1122232T1 (hr) |
| DK (1) | DK3312181T3 (hr) |
| ES (1) | ES2751913T3 (hr) |
| HR (1) | HRP20191961T1 (hr) |
| HU (1) | HUE047430T2 (hr) |
| IL (1) | IL256252B (hr) |
| LT (1) | LT3312181T (hr) |
| MX (1) | MX2017016690A (hr) |
| MY (1) | MY197499A (hr) |
| PH (1) | PH12017502253A1 (hr) |
| PL (1) | PL3312181T3 (hr) |
| PT (1) | PT3312181T (hr) |
| RS (1) | RS59497B1 (hr) |
| RU (1) | RU2712968C2 (hr) |
| SG (1) | SG11201710345VA (hr) |
| SI (1) | SI3312181T1 (hr) |
| TW (1) | TWI697496B (hr) |
| UA (1) | UA120006C2 (hr) |
| WO (1) | WO2016204268A1 (hr) |
| ZA (1) | ZA201708566B (hr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI725408B (zh) | 2018-04-20 | 2021-04-21 | 美商美國禮來大藥廠 | 多巴胺d1受體正向異位調節劑 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7067507B2 (en) * | 2001-06-12 | 2006-06-27 | Pharmacia & Upjohn Company | Macrocycles useful in the treatment of Alzheimer's disease |
| ATE486842T1 (de) | 2002-03-12 | 2010-11-15 | Merck Sharp & Dohme | Substituierte amide |
| WO2004000837A1 (ja) * | 2002-06-25 | 2003-12-31 | Sumitomo Pharmaceuticals Co., Ltd. | 新規なベンズオキサゾリノン誘導体 |
| CA2555812A1 (en) * | 2004-02-13 | 2005-09-01 | President And Fellows Of Harvard College | 3-3-di-substituted-oxindoles as inhibitors of translation initiation |
| EP1719761A4 (en) | 2004-02-23 | 2007-10-10 | Dainippon Sumitomo Pharma Co | NEW HETEROCYCLIC CONNECTION |
| JP4914346B2 (ja) * | 2004-05-27 | 2012-04-11 | ユセベ ファルマ ソシエテ アノニム | ベンズオキサゾロン誘導体、その調製方法及びその使用 |
| CL2007002097A1 (es) | 2006-07-20 | 2008-01-18 | Smithkline Beecham Corp | Compuestos derivados de pirrolidina o morfolina antagonistas de urotensina ii; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar insuficiencia cardiaca congestiva, insuficiencia cardiaca isquemica, angina, isquemia del miocardio, vejiga hiperactiva, asma y/o copd, entre otras. |
| PE20081229A1 (es) * | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| KR101875238B1 (ko) * | 2010-06-24 | 2018-07-05 | 다케다 야쿠힌 고교 가부시키가이샤 | 포스포디에스테라아제 （ｐｄｅｓ） 저해제로서의 융합 헤테로시클릭 화합물 |
| AR095883A1 (es) * | 2013-04-18 | 2015-11-18 | Astellas Pharma Inc | Compuestos de acetamida heterocíclica |
-
2016
- 2016-06-16 AR ARP160101804A patent/AR105025A1/es unknown
- 2016-06-17 UA UAA201800508A patent/UA120006C2/uk unknown
- 2016-06-17 KR KR1020177036276A patent/KR102591169B1/ko active IP Right Grant
- 2016-06-17 HU HUE16811742A patent/HUE047430T2/hu unknown
- 2016-06-17 DK DK16811742T patent/DK3312181T3/da active
- 2016-06-17 ES ES16811742T patent/ES2751913T3/es active Active
- 2016-06-17 TW TW105119205A patent/TWI697496B/zh not_active IP Right Cessation
- 2016-06-17 MY MYPI2017704807A patent/MY197499A/en unknown
- 2016-06-17 MX MX2017016690A patent/MX2017016690A/es active IP Right Grant
- 2016-06-17 SG SG11201710345VA patent/SG11201710345VA/en unknown
- 2016-06-17 SI SI201630411T patent/SI3312181T1/sl unknown
- 2016-06-17 JP JP2017524854A patent/JP6658753B2/ja active Active
- 2016-06-17 US US15/737,564 patent/US10426784B2/en active Active
- 2016-06-17 WO PCT/JP2016/068080 patent/WO2016204268A1/ja active Application Filing
- 2016-06-17 LT LTEP16811742.2T patent/LT3312181T/lt unknown
- 2016-06-17 CN CN201680034335.2A patent/CN107635996B/zh active Active
- 2016-06-17 PT PT168117422T patent/PT3312181T/pt unknown
- 2016-06-17 CA CA2989982A patent/CA2989982C/en active Active
- 2016-06-17 EP EP16811742.2A patent/EP3312181B1/en active Active
- 2016-06-17 RU RU2018101861A patent/RU2712968C2/ru active
- 2016-06-17 AU AU2016279518A patent/AU2016279518B2/en active Active
- 2016-06-17 PL PL16811742T patent/PL3312181T3/pl unknown
- 2016-06-17 RS RS20191427A patent/RS59497B1/sr unknown
- 2016-06-17 CN CN202010083916.3A patent/CN111205292B/zh active Active
-
2017
- 2017-12-11 PH PH12017502253A patent/PH12017502253A1/en unknown
- 2017-12-11 IL IL256252A patent/IL256252B/en active IP Right Grant
- 2017-12-15 ZA ZA2017/08566A patent/ZA201708566B/en unknown
-
2018
- 2018-01-17 CO CONC2018/0000431A patent/CO2018000431A2/es unknown
-
2019
- 2019-10-16 CY CY20191101083T patent/CY1122232T1/el unknown
- 2019-10-30 HR HRP20191961TT patent/HRP20191961T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020040989A5 (hr) | ||
| PE20141974A1 (es) | Compuestos de heterociclilo | |
| JP2014525432A5 (hr) | ||
| HRP20201469T1 (hr) | Derivati tetrahidroizokinolina | |
| PE20141938A1 (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
| PE20160664A1 (es) | Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina | |
| PE20141557A1 (es) | Derivado de pirazoloquinolina | |
| NZ594851A (en) | Pyridazinone compounds | |
| PE20090493A1 (es) | DERIVADOS DE LA 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA | |
| PE20141308A1 (es) | Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a | |
| PE20121352A1 (es) | Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3 | |
| MA38391B1 (fr) | Dérivés de pyridinyl et triazolone pyridinyl de fusion | |
| MY192029A (en) | 6, 7-dihydropyrazolo [1,5-()]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors | |
| JP2018513191A5 (hr) | ||
| HRP20161797T1 (hr) | Spojevi 1,3-oksazolidina ili 1,3-oksazinana kao antagonisti receptora oreksina | |
| HRP20191961T1 (hr) | Spoj imidazodiazepina | |
| MX369820B (es) | Derivados de etinil-imidazolin-2,4-diona como moduladores del receptor 4 de glutamato metabotropico (mglur4). | |
| PE20170008A1 (es) | Compuestos heteroaromaticos y su uso como ligandos de dopamina d1 | |
| AR074226A1 (es) | Octahidrociclopenta[c]pirrol-4-aminas sustituidas como bloqueantes de los canales de calcio, composiciones farmaceuticas que las comprenden y el uso de las mismas para el tratamiento del dolor. | |
| TN2016000188A1 (fr) | Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs. | |
| JP2014511355A5 (hr) | ||
| PE20210052A1 (es) | Moduladores alostericos de espiropiperidina de receptores nicotinicos de acetilcolina | |
| JP2014520153A5 (hr) | ||
| JP2019537581A5 (hr) | ||
| PH12016501481B1 (en) | Ethynyl derivatives |